Literature DB >> 24682792

Infrastructures, treatment modalities, and workload of radiation oncology departments in Spain with special attention to prostate cancer.

J López Torrecilla1, A Zapatero, I Herruzo, F A Calvo, M A Cabeza, A Palacios, A Guerrero, A Hervás, P Lara, B Ludeña Martínez, E Del Cerro Peñalver, G Nagore, G Sancho, J L Mengual, M Mira, A Mairiño, P Samper, S Pérez, I Castillo, J C Martínez Cedrés, E Ferrer, S Rodriguez, X Maldonado, A Gómez Caamaño, C Ferrer.   

Abstract

AIM: The purpose of the study was to describe infrastructures, treatment modalities, and workload in radiation oncology (RO) in Spain, referred particularly to prostate cancer (PC).
METHODS: An epidemiologic, cross-sectional study was performed during 2008-2009. A study-specific questionnaire was sent to the 108 RO-registered departments.
RESULTS: One hundred and two departments answered the survey, and six were contacted by telephone. Centers operated 236 treatment units: 23 (9.7 %) cobalt machines, 37 (15.7 %) mono-energetic linear accelerators, and 176 (74.6 %) multi-energy linear accelerators. Sixty-one (56.4 %) and 33 (30.5 %) departments, respectively, reported intensity-modulated radiation therapy (IMRT) and image-guided RT (IGRT) capabilities; three-dimensional-conformal RT was used in 75.8 % of patients. Virtual simulators were present in 95 departments (88.0 %), 35 use conventional simulators. Fifty-one departments (47.2 %) have brachytherapy units, 38 (35.2 %) perform prostatic implants. Departments saw a mean of 24.9 new patients/week; the number of patients treated annually was 102,054, corresponding to 88.4 % of patients with a RT indication. In 56.5 % of the hospitals, multidisciplinary teams were available to treat PC.
CONCLUSIONS: Results provide an accurate picture of current situation of RO in Spain, showing a trend toward the progressive introduction of new technologies (IMRT, IGRT, brachytherapy).

Entities:  

Mesh:

Year:  2013        PMID: 24682792     DOI: 10.1007/s12094-013-1121-2

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  13 in total

Review 1.  A global strategy for radiotherapy: a WHO consultation.

Authors:  A Porter; A Aref; Z Chodounsky; A Elzawawy; N Manatrakul; T Ngoma; C Orton; E Van't Hooft; K Sikora
Journal:  Clin Oncol (R Coll Radiol)       Date:  1999       Impact factor: 4.126

2.  Infrastructure of radiotherapy in Spain: a minimal standard of radiotherapy resources.

Authors:  R Esco; A Palacios; J Pardo; A Biete; J A Carceller; C Veiras; G Vazquez
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-06-01       Impact factor: 7.038

3.  Patterns of care for brachytherapy in Europe: updated results.

Authors:  Ferran Guedea; Jack Venselaar; Peter Hoskin; Taran Paulsen Hellebust; Didier Peiffert; Bradley Londres; Montse Ventura; Jean-Jacques Mazeron; Erik Van Limbergen; Richard Pötter; Gyorgy Kovacs
Journal:  Radiother Oncol       Date:  2010-10-13       Impact factor: 6.280

4.  Infrastructure of radiation oncology in France: a large survey of evolution of external beam radiotherapy practice.

Authors:  Sophie Ruggieri-Pignon; Thierry Pignon; Michel Marty; Marie-Hélène Rodde-Dunet; Brigitte Destembert; Béatrice Fritsch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-02-01       Impact factor: 7.038

5.  Practice patterns in the management of prostate cancer in Spain: results from a national survey among radiation oncologists in 2009.

Authors:  Almudena Zapatero; José López-Torrecilla; Ismael Herruzo; Felipe A Calvo
Journal:  Clin Transl Oncol       Date:  2012-08-02       Impact factor: 3.405

6.  Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.

Authors:  Almudena Zapatero; Francisco Valcárcel; Felipe A Calvo; Rosa Algás; Amelia Béjar; Javier Maldonado; Salvador Villá
Journal:  J Clin Oncol       Date:  2005-09-20       Impact factor: 44.544

7.  Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality.

Authors:  N Larrañaga; J Galceran; E Ardanaz; P Franch; C Navarro; M J Sánchez; R Pastor-Barriuso
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

8.  [Use of radiotherapy in South-Eastern Norway Regional Health Authority].

Authors:  Vidar Jetne; Stein Kvaløy; Sigbjørn Smeland; Tom Børge Johannesen; Kjell Magne Tveit
Journal:  Tidsskr Nor Laegeforen       Date:  2009-12-17

Review 9.  The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001--summary and conclusions.

Authors:  Ulrik Ringborg; David Bergqvist; Bengt Brorsson; Eva Cavallin-Ståhl; Jeanette Ceberg; Nina Einhorn; Jan-Erik Frödin; Johannes Järhult; Gunilla Lamnevik; Christer Lindholm; Bo Littbrand; Anders Norlund; Urban Nylén; Måns Rosén; Hans Svensson; Torgil R Möller
Journal:  Acta Oncol       Date:  2003       Impact factor: 4.089

10.  Estimates of the cancer incidence and mortality in Europe in 2006.

Authors:  J Ferlay; P Autier; M Boniol; M Heanue; M Colombet; P Boyle
Journal:  Ann Oncol       Date:  2007-02-07       Impact factor: 32.976

View more
  2 in total

1.  Management of prostate cancer patients following radiation therapy after radical surgery referred from urology to radiation oncology departments in Spain.

Authors:  A Gómez Caamaño; A Zapatero; J López Torrecilla; X Maldonado
Journal:  Clin Transl Oncol       Date:  2015-11-30       Impact factor: 3.405

2.  Evaluation of the utilization of external radiotherapy in the treatment of localized prostate cancer in Andalusia, Spain.

Authors:  José Expósito; Isabel Linares; Isabel Castillo; Miguel Martínez; Pilar Vargas; Ismael Herruzo; José Antonio Medina; Amalia Palacios; Eloísa Bayo; Francisco Peracaula; Javier Jaén; José Antonio Sánchez; María José Ortiz
Journal:  Radiat Oncol       Date:  2015-12-30       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.